Andrew J. Cowan, MD

home / authors / andrew-j-cowan-md

Articles

Determining the Right Patients with NDMM for Autologous Stem Cell Transplant

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD

September 22nd 2022

Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD

September 15th 2022

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD

September 15th 2022

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells

Andrew J. Cowan, MD

February 17th 2020

The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.

<1 2